Errata (DOI:10.1016/j.ijrobp.2007.03.041);Prevention of Radiochemotherapy-Induced Esophagitis With Glutamine: Results of a Pilot Study

International Journal of Radiation Oncology Biology Physics

Volumn 69, Issue 2, 2007, Pages 342-349

  Algara, Manuel ^a,b   Rodríguez, Nuria ^a   Viñals, Pedro ^a   Lacruz, Martí ^a,b   Foro, Palmira ^a   Reig, Anna ^a   Quera, Jaume ^a,b   Lozano, Joan ^a   Fernández Velilla, Enric ^a   Membrive, Ismael ^a   Dengra, Josefa ^a   Sanz, Xavier ^a  

^a HOSPITAL DE L ESPERANÇA   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

Acute effects; Esophagitis; Glutamine; Radiotherapy

Indexed keywords

CHEMOTHERAPY; ONCOLOGY; PATIENT MONITORING; RADIOTHERAPY; TOXICITY;

ESOPHAGITIS; GLUTAMINE; LUNG CANCER;

MEDICAL PROBLEMS;

CARBOPLATIN; CISPLATIN; ETOPOSIDE; GLUTAMINE; NAVELBINE; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; DOSIMETRY; ESOPHAGITIS; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIATION DOSE;

EID: 34548499680     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.01.001     Document Type: Erratum

References (49)

1. Bradley J., and Movsas B. Radiation esophagitis: Predictive factors and preventive strategies. Semin Radiat Oncol 14 (2004) 280-286
2. Furuse K., Fukuoka M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 17 (1999) 2692-2699
3. Curran W.J., Scott C.B., Langer C.J., et al. Long-term benefits is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III non-small cell lung cancer: RTOG 9410. [Abstract]. Proc Am Soc Clin Oncol 22 (2003) 621
4. Pierre F., Maurice P., Gilles R., et al. A randomized phase III trial of sequential chemo-radiotherapy versus concurrent chemo-radiotherapy in locally advanced non-small cell lung cancer (NSCLC) (GLOT-GFPCNPC 95-01 study). [Abstract]. Proc Am Soc Clin Oncol 20 (2001) 312
5. Pignon J.P., Arriagada R., Ihde D.C., et al. A meta-analysis of thoracic radiotherapy for small cell lung cancer. N Engl J Med 327 (1992) 1618-1624
6. Turrisi A.T., Kim K., Blum R., et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small cell lung cancer treated concurrently with cisplatin and etoposide. New Engl J Med 340 (1999) 265-271
7. Chapet O., Fraas B.A., and Ten Haken R.K. Multiple fields may offer better esophagus sparing without increased probability of lung toxicity in optimized IMRT of lung tumors. Int J Radiat Oncol Biol Phys 65 (2006) 255-265
8. Bergstrom J., Furst P., Noree L., et al. Intracellular free amino acid concentration in human muscle tissue. J Appl Physiol 36 (1974) 693-697
9. Lacely J., and Wilmore D. Is glutamine a conditionally essential amino acid?. Nutr Rev 48 (1990) 297-309
10. Van Der Hulst R., Kreel B., Von Meyenfeldt M., et al. Glutamine and the preservation of gut integrity. Lancet 341 (1993) 1363-1365
11. Shewchuk L., Baracos V., Field C., et al. Dietary L-glutamine supplementation reduces the growth of the Morris Hepatoma 7777 in exercise-trained and sedentary rats. J Nutr 127 (1997) 158-166
12. Souba W.W., Klimberg V.S., Hautamaki R.D., et al. Oral glutamine reduces bacterial translocation following abdominal radiation. J Surg Res 48 (1990) 1-5
13. Klimberg V.S., Salloum R.M., Kasper M., et al. Oral glutamine accelerates healing of the small intestine and improves outcome after whole abdominal radiation. Arch Surg 125 (1990) 1040-1045
14. Klimberg V.S., Souba W.W., Dolson D.J., et al. Prophylactic glutamine protects the intestinal mucosa from radiation injury. Cancer 66 (1990) 62-68
15. Shou J., Lieberman M.D., Hofmann K., et al. Dietary manipulation of methotrexate-induced enterocolitis. JPEN J Parenter Enteral Nutr 15 (1991) 307-312
16. Huang E.Y., Wan Leung S., Wang C.J., et al. Oral glutamine to alleviate radiation-induced oral mucositis: A pilot randomized trial. Int J Radiat Oncol Biol Phys 46 (2000) 535-539
17. Bowden P., Fischer R., Mac M.M., et al. Measurement of lung tumor volumes using three-dimensional computer planning software. Int J Radiat Oncol Biol Phys 53 (2002) 566-573
18. Rodríguez N., Foro P., Sanz X., et al. Target contouring protocol for 3D conformal radiotherapy in lung cancer. Int J Radiat Oncol Biol Phys 65 (2006) 1275-1276
19. Rodríguez G., Lock M., D'Souza D., et al. Prediction of radiation pneumonitis by dose-volume histogram parameters in lung cancer-A systematic review. Radiother Oncol 71 (2004) 127-138
20. Metha V. Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: Pulmonary function, prediction, and prevention. Int J Radiat Oncol Biol Phys 63 (2005) 5-24
21. Cox J.D., Stetz J., Pajak T.F., et al. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31 (1995) 1341-1346
22. Marrugat J., Sanz F., Algara M., et al. Metodología de los ensayos en radioterapia [Methodology in radiotherapy trials]. In: Sanchiz F., Millá A., and Valls A. (Eds). Tratado de radioterapia oncológica. 1st ed. (1994), Espaxs, Barcelona 147-161
23. Sachs L. Applied statistics: A handbook of techniques (1978), Springer-Verlag, New York
24. Sur R.K., Kochhar R., and Singh D.P. Oral sucralfate in acute radiation oesophagitis. Acta Oncol 33 (1994) 61-63
25. Sasse A.D., Clark L.G., Sasse F.C., et al. Amifostine reduces side effects and improves complete response rate during radiotherapy: Results of a meta-analysis. Int J Radiat Oncol Biol Phys 64 (2006) 784-791
26. Bonzzetti F., Biganzoli L., and Gavazzi C. Glutamine supplementation in cancer patients receiving chemotherapy: A double-blind randomized study. Nutrition 13 (1997) 748-751
27. Daniele B., Perrone F., and Gallo C. Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: A double blind, placebo controlled, randomised trial. Gut 48 (2001) 28-33
28. Kozelsky T., Meyers G., Sloan J., et al. Phase III double-blind study of glutamine versus placebo for the prevention of acute diarrhea in patients receiving pelvic radiation therapy. J Clin Oncol 21 (2003) 1669-1674
29. Van Zaanen H.C., Van der Lelie H., Timmer J.G., et al. Parenteral glutamine dipeptide supplementation does not ameliorate chemotherapy-induced toxicity. Cancer 74 (1994) 2879-2884
30. Jebb S.A., Osborne R.J., Maughan T.S., et al. 5-fluorouracil and folinic acid-induced mucositis: No effect of oral glutamine supplementation. Br J Cancer 70 (1994) 732-735
31. Okuno S., Woodhouse C., Loprinzi C., et al. Phase III controlled evaluation of glutamine for decreasing stomatitis in patients receiving fluorouracil (5-FU)-based chemotherapy. Am J Clin Oncol 22 (1999) 258-261
32. Anderson P.M., Schroeder G., and Skubitz K.M. Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy. Cancer 83 (1998) 1433-1439
33. Anderson P.M., Ramsay N.K., Shu X.O., et al. Effect of low-dose oral glutamine on painful stomatitis during bone marrow transplantation. Bone Marrow Transplant 22 (1998) 339-344
34. Cerchietti L.C., Navigante A.H., Lutteral M.A., et al. Double-blind, placebo-controlled trial on intravenous L-Alanyl-L-Glutamine in the incidence of oral mucositis following chemoradiotherapy in patients with head-and-neck cancer. Int J Radiat Oncol Biol Phys 65 (2006) 1330-1337
35. a intestinal cells. JPEN J Parenter Enteral Nutr 23 (1999) 136-139
36. Klimberg V.S., and Mc Clellan J.L. Glutamine, cancer, and its therapy. Am J Surg 172 (1996) 418-424
37. Ziegler T., Benfell K., Smith R., et al. Safety and metabolic effects of L-glutamine administration in humans. JPEN J Parenter Enteral Nutr 14 (1990) 137S-146S
38. Byhardt R.W., Scott C., Sause W.T., et al. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 42 (1998) 469-478
39. Komaki R., Seiferheld W., Ettinger D., et al. Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small cell lung cancer. Long-term follow up of RTOG 92-04. Int J Radiat Oncol Biol Phys 53 (2002) 548-557
40. Dillman R.O., Seagren S.L., Propert K.J., et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small cell lung cancer. N Engl J Med 323 (1990) 940-945
41. Sause W., Kolesar P., Taylor IV S., et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117 (2000) 358-364
42. Singh A.K., Lockett M.A., and Bradley J.D. Predictors of radiation-induced esophageal toxicity in patients with non-small cell lung cancer treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 55 (2003) 337-341
43. Hirota S., Tsujino K., Endo M., et al. Dosimetric predictors of radiation esophagitis in patients treated for non-small cell lung cancer with carboplatin/paclitaxel/radiotherapy. Int J Radiat Oncol Biol Phys 51 (2001) 291-295
44. Choy H., Akerley W., Safran H., et al. Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small cell lung cancer. J Clin Oncol 16 (1998) 3316-3322
45. Wei X., Liu H., Tucker S.L., et al. Risk factors for acute esophagitis in non-small cell lung cancer patients trated with concurrent chemotherapy and three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 66 (2006) 100-107
46. Bradley J., Deasy J.O., Bentzen S., et al. Dosimetric correlates for acute esophagitis in patients treated with radiotherapy for lung carcinoma. Int J Radiat Oncol Biol Phys 58 (2004) 1106-1113
47. Kim T.H., Cho K.H., Pyo H.R., et al. Dose-volumetric parameters of acute esophageal toxicity in patients with lung cancer treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 62 (2005) 995-1002
48. Maguire P.D., Sibley G.S., Zhou S.M., et al. Clinical and dosimetric predictors of radiation-induced esophageal toxicity. Int J Radiat Oncol Biol Phys 45 (1999) 97-103
49. Rosenman J.G., Halle J.S., Socinski M.A., et al. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: Technical issues and results of a phase I/II trial. Int J Radiat Oncol Biol Phys 54 (2002) 348-356